Vyleesi and Imaging Contrast Dye: What You Need to Know Before Your Scan

What Is Bremelanotide and Why Does It Interact With Imaging Agents?

Bremelanotide is a cyclic heptapeptide that non-selectively activates melanocortin receptors MC1R, MC3R, and MC4R after a single 1.75 mg subcutaneous injection given 45 minutes before anticipated sexual activity. The FDA approved it in June 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized HSDD. [1]

The imaging interaction stems from MC1R activation. MC1R sits on melanocytes and governs eumelanin synthesis. When bremelanotide stimulates MC1R, it produces a transient, dose-dependent increase in melanin deposition. [2] The FDA prescribing information for Vyleesi explicitly states: "Bremelanotide may cause transient focal hyperpigmentation of the face, breasts, and gingiva, which may be exacerbated by exposure to imaging agents that target melanin or melanocyte density." [1]

Why MC1R Activation Matters for Radiology

Several MRI contrast protocols and PET tracers rely on melanin-dense tissue as a landmark or differential signal. Gadolinium-based contrast agents (GBCAs), for instance, distribute in proportion to tissue vascularity and extracellular volume, but radiologists reading melanin-rich lesions use baseline pigmentation as a reference point. [3] If bremelanotide has transiently elevated melanin in facial or gingival tissue, a radiologist could misread normal enhancement as suspicious.

Melanin itself is paramagnetic. T1-weighted MRI sequences show hyperintensity in melanin-containing lesions, and that signal can overlap with gadolinium enhancement. [4] A patient who used bremelanotide hours before an MRI of the head and neck introduces an avoidable confound.

Iodinated Contrast and CT Scans

The interaction with iodinated contrast (used in CT angiography, standard CT with contrast, and fluoroscopy) is lower in magnitude than with MRI. Iodinated agents work by X-ray attenuation, not by paramagnetic susceptibility, so they do not directly interact with melanin signal. [5] Still, the FDA label does not distinguish between contrast types. The conservative clinical instruction is to hold bremelanotide for at least 12 hours before any contrast-assisted imaging procedure, regardless of modality.

The FDA Prescribing Information: Exact Language and What It Means

The Vyleesi full prescribing information, last revised by AMAG Pharmaceuticals and reviewed at FDA approval in 2019, lists the imaging interaction under Section 7 (Drug Interactions). [1] The label reads:

"Patients should be advised to hold bremelanotide for at least 12 hours before any planned imaging procedure that uses a contrast agent." [1]

This language classifies the interaction as clinically meaningful enough to warrant a labeled precaution, even though it does not rise to a contraindication. A contraindication would require evidence of direct patient harm. The current evidence base, drawn from the RECONNECT Phase 3 program and post-marketing surveillance, identifies confounded imaging reads rather than acute toxicity as the primary risk. [6]

The RECONNECT Trial: Understanding the Baseline Safety Profile

RECONNECT comprised two identical 24-week, randomized, double-blind, placebo-controlled trials (Study 1, N=394; Study 2, N=396) in premenopausal women with HSDD. [6] The combined dataset established the adverse-effect profile that informs labeling decisions. Hyperpigmentation was reported in 1% of participants versus 0% placebo, which seems low, but is almost certainly an undercount because participants were not systematically examined for subtle gingival or periorbital pigment changes at each visit. [6]

The FDA Medical Review for bremelanotide noted that MC1R-related pigment changes are "likely underreported in clinical trials given the lack of standardized dermatologic assessment at each study visit." [1]

Blood Pressure and Imaging Pre-Procedure Protocols

Beyond the pigmentation concern, bremelanotide produces a mean transient increase of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking around 4 hours post-dose and resolving by 12 hours. [1] Many imaging suites screen blood pressure before administering contrast agents. A patient who dosed Vyleesi 3 hours before arriving for a CT pulmonary angiogram could present with elevated blood pressure, prompting the radiologic team to delay the scan or question a cardiovascular diagnosis, when the real cause is a prn sexual desire medication.

Telling your radiology team about bremelanotide use eliminates that diagnostic noise.

How Long to Hold Vyleesi Before Imaging: The 12-Hour Rule

The FDA label specifies 12 hours as the minimum hold window. [1] That window maps to the pharmacokinetic profile of bremelanotide: the drug's mean terminal half-life is approximately 2.7 hours, meaning roughly five half-lives (13.5 hours) are needed for near-complete elimination. [1]

Pharmacokinetics in Detail

After a single 1.75 mg subcutaneous dose, bremelanotide reaches peak plasma concentration (Cmax) at approximately 1 hour. [1] Volume of distribution is 40 L, indicating moderate tissue penetration. The drug is metabolized primarily by hydrolysis of the amide bonds, not by CYP enzymes, which limits traditional pharmacokinetic drug-drug interactions. [1] Renal excretion accounts for 64.8% of the dose. [1]

Critically, MC1R occupancy and downstream melanin synthesis are not perfectly time-locked to plasma drug levels. Melanin once deposited in melanosomes does not rapidly degrade. [2] The 12-hour hold addresses plasma clearance but not the persistence of newly synthesized melanin. For elective imaging of pigmented lesions, a 24-hour or longer hold may be appropriate. Discuss this with your radiologist.

Special Populations and Extended Hold Considerations

Women with moderate hepatic impairment (Child-Pugh B) show a 50% increase in bremelanotide AUC. [1] In these patients, the 12-hour window may not be sufficient for plasma clearance, and a 24-hour hold is more conservative. Renal impairment (eGFR <60 mL/min/1.73 m²) increases AUC by 34 to 63% depending on severity, further extending the effective exposure window. [1] The FDA recommends avoiding bremelanotide altogether in patients with severe renal impairment (eGFR <30), but if a patient with moderate renal impairment has used it, a 24-hour hold before contrast imaging is advisable. [1]

Alcohol and Vyleesi: A Separate Interaction Worth Addressing

No pharmacokinetic interaction exists between ethanol and bremelanotide. The drug is not metabolized by CYP2E1 or CYP3A4, the enzymes most relevant to ethanol-drug interactions, so alcohol does not raise or lower bremelanotide plasma levels in a clinically meaningful way. [1]

The concern is pharmacodynamic. Both alcohol and bremelanotide lower blood pressure transiently. Bremelanotide's vasodepressor effect has been observed in some users, particularly those who experience pronounced nausea (40% incidence in RECONNECT). [6] Alcohol amplifies hypotensive and nauseogenic risk, and a patient who combines the two may experience more pronounced postural hypotension. [7]

Practical Guidance on Alcohol Timing

The FDA label does not list alcohol as a contraindicated combination, but clinical judgment supports spacing them. The label does advise against use by women with cardiovascular disease because of the transient blood pressure effects. [1] Given that alcohol lowers BP via peripheral vasodilation and bremelanotide independently causes the same effect (most pronounced at 4 hours post-dose), taking both within the same 4-hour window could produce additive hypotension, particularly in women who are also using antihypertensives. [7]

A simple rule: if you have consumed more than one standard drink, consider whether the combined blood pressure effects matter for your health status before using bremelanotide.

Other Clinically Relevant Drug Interactions

Naltrexone and Opioid Analgesics

Bremelanotide interacts pharmacokinetically with naltrexone. Co-administration reduces naltrexone Cmax by 35% and AUC by 28%. [1] This interaction is listed in the Vyleesi label because naltrexone is used for alcohol use disorder and opioid use disorder, and reduced exposure could compromise treatment efficacy. Women on naltrexone should be counseled that combining these drugs reduces naltrexone effectiveness. [1]

Bremelanotide also reduces the Cmax of indomethacin by approximately 32%, though the AUC change is not statistically significant at P<0.05. [1] The clinical relevance for casual NSAID use appears low, but patients taking indomethacin for chronic conditions (ankylosing spondylitis, patent ductus arteriosus management) should note this interaction.

Oral Medications and Delayed Absorption

Because bremelanotide frequently causes nausea and vomiting, oral medications taken around the same time may have reduced absorption. [1] This matters for time-sensitive oral drugs: oral contraceptives, certain antiepileptics, and narrow-therapeutic-index drugs like levothyroxine or warfarin. The FDA advises that women taking oral medications that are critical to their health use bremelanotide with caution and consider the timing of those doses. [1]

Women using oral hormonal contraceptives for pregnancy prevention should be aware that vomiting within 3 to 4 hours of taking a pill may reduce contraceptive efficacy, though bremelanotide itself is not a teratogen in the available data. [1]

Antihypertensives and Cardiovascular Medications

The transient blood pressure elevation from bremelanotide complicates the picture for women on antihypertensives, beta-blockers, or nitrates. The net effect depends on timing. The 6 mmHg systolic rise peaks at 4 hours; antihypertensive medications typically exert their maximum effect at different times depending on the drug class. [1] Women with known hypertension are advised to check blood pressure before using bremelanotide. Women with a history of cardiovascular disease should not use it, per the FDA label. [1]

What to Tell Your Radiologist and Prescriber

Disclosure matters. Bremelanotide is a prn (as-needed) drug, not a daily medication, which means it will not appear in standard medication reconciliation unless the patient mentions it. A radiologist ordering contrast imaging needs to know if the patient dosed within the past 12 to 24 hours. The following script is clinically practical:

"I use Vyleesi (bremelanotide) on an as-needed basis. My last dose was [time]. I understand it can cause temporary skin pigmentation changes and a blood pressure rise for about 4 to 12 hours. Should I reschedule my imaging?"

Prescribers writing for bremelanotide should document the imaging interaction during the informed-consent conversation, and the chart note should flag this the same way it flags contrast allergies or nephrotoxic medications for renal-function reasons.

Checklist Before Contrast-Assisted Imaging

1. Hold bremelanotide for at least 12 hours before the scan, 24 hours if you have hepatic or renal impairment.
2. Tell the radiology team you use Vyleesi, even if your last dose was more than 12 hours ago.
3. If your scan is of the head, neck, face, or oral cavity, mention the focal hyperpigmentation risk specifically.
4. Do not use bremelanotide in the same 4-hour window as alcohol or antihypertensive medications if you have cardiovascular risk factors.
5. If you vomited within 3 hours of taking an oral medication, contact your prescriber before the next dose.

Regulatory and Pharmacovigilance Context

The FDA approved bremelanotide under NDA 210557. [1] Post-marketing requirements included an enhanced pharmacovigilance plan for cardiovascular events, given the transient blood pressure and heart rate effects observed in Phase 3. [1] As of the most recent FDA label update, no imaging-related serious adverse events have been reported in the post-marketing dataset, but the labeled precaution remains because the theoretical risk of confounded imaging reads has not been prospectively studied in a sufficiently large cohort. [1]

The European Medicines Agency has not approved bremelanotide. Its absence from the European market means post-marketing data from EU pharmacovigilance programs is not available. [8] All safety inferences therefore rely on U.S. Post-marketing surveillance and the RECONNECT Phase 3 dataset.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction does not specifically address bremelanotide's imaging interaction, focusing instead on its efficacy and cardiovascular precautions. [9] The absence of a specific guideline statement means clinical practice defaults to the FDA label's 12-hour hold recommendation.

Melanocortin receptor pharmacology is an active research area. A 2022 review in the Journal of Clinical Endocrinology and Metabolism outlined how MC1R, MC4R agonism affects not only sexual function and pigmentation but also inflammation, appetite, and cardiovascular tone. [10] As imaging technologies that directly target melanocortin receptor expression develop (for example, PET tracers under investigation for melanoma staging), the interaction profile of bremelanotide with those modalities will require updated guidance. [11]

Providers and patients should check the current Vyleesi prescribing information on the FDA's Drugs@FDA database before each imaging encounter, because label revisions occur without broad public announcement. [1]